| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -7.6 | -9.7 |
| EPS (diluted, $ a share) | $-0.08 | $-0.10 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CNTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Context Therapeutics Inc.: key numbers
- Share price
- $0.1659Close, Nov 16
- Market cap
- $15.2M
- Shares outstanding
- 91.88MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Context Therapeutics Inc.
All →Context Therapeutics Financial Results
Context Therapeutics reported Q3 2026 financial results and provided a clinical update on its CTIM-76 program, which showed a 22% confirmed ORR and 5.6 months median PFS in platinum-resistant ovarian cancer. The company ended the quarter with $34.4 million in cash, providing a runway into Q4 2027.
- Term
- Q3 2026
“CTIM-76 continues to show promising activity in patients with PROC who had received a median of six prior lines of therapy. Our Phase 1b strategy is to evaluate CTIM-76 in patients with no more than five prior lines of therapy. These less heavily pretreated patients generally have lower tumor burden and better T cell fitness, providing a rationale to evaluate whether treatment in this population, together with Q3W dosing, can deliver greater clinical benefit and improved tolerability.”
Martin Lehr, Chief Executive Officer